Skip to content

A Randomized Controlled Study on the Efficacy and Safety of Chinese Medicine Xinju Nebulized Liquid in the Treatment of Allergic Rhinitis

Research on advantage breakthrough of the theory of ''preventive treatment of disease'' in the prevention and treatment of allergic rhinitis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045156
Enrollment
Unknown
Registered
2021-04-07
Start date
2021-04-12
Completion date
Unknown
Last updated
2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.In accordance with the diagnostic criteria of Chinese medicine and western medicine for allergic rhinitis; 2.Ages 18 to 65 years; 3.Subjects will sign the informed consent form and volunteer to participate in the study; 4.Subjects are able to complete the case record form and other related records as required.

Exclusion criteria

Exclusion criteria: 1.Rhinitis subjects with definite etiology, such as acute rhinitis, vasomotor rhinitis, autonomic nervous rhinitis, eosinophilic non-allergic rhinitis, allergic sinusitis, drug rhinitis, etc. 2.Subjects with anatomic abnormalities such as deviation of nasal septum and stenosis of nasal cavity. 3.Nasal polyps, acute and chronic sinusitis, nasal foreign bodies or other space occupying lesions, etc. 4.Women who are pregnant or lactating or who intend to be pregnant. 5.Respiratory disease such as asthma, cardiovascular disease, hematological disease or serious disease affecting survival, such as malignant tumor or AIDS. 6.Subjects who will be involved in other related researches of allergic rhinitis. 7.Due to mental or behavioral disorders,subjects cannot cooperate with the experimenters and investigators. 8.Subjects who will lose follow-up due to frequent changes in the working palace.

Design outcomes

Primary

MeasureTime frame
total nasal symptom score;

Secondary

MeasureTime frame
the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire;Physical sign score;Medication scores;Rhinitis control assessment test;Nasal resistance;

Countries

China

Contacts

Public ContactChen Wenyong

Guangdong Provincial Hospital of Chinese Medicine

wenyongch@163.com+86 13710328628

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026